Ingenix Raises €9M
Ingenix Raises €9M to Transform Clinical Trial Simulations with AI
Warsaw-based healthtech startup Ingenix has secured €9 million in seed funding to advance its AI-powered platform that simulates clinical trials, potentially reshaping the way pharmaceuticals are developed and tested. The round was led by Inovo.vc, with participation from OTB Ventures and the International Finance Corporation (IFC).
Simulating Drug Trials with Artificial Intelligence
Ingenix is building a platform that replicates the entire process of clinical trials—from molecular interaction to population-level impact—using advanced AI models. This innovation is aimed at tackling one of the pharmaceutical industry’s most pressing challenges: the high failure rate and cost of traditional drug trials.
Subscribe to Startup Digest to stay ahead with the latest news, investments, and must-attend events.
The pharmaceutical industry invests around $50 billion annually in clinical testing, yet 90% of drugs fail to gain regulatory approval due to unexpected outcomes or adverse effects. Ingenix’s platform is designed to simulate and predict these outcomes with far greater accuracy, potentially saving time, money, and lives.
Co-founder and CEO Piotr Surma, who previously co-founded Applica (acquired by Snowflake in 2022), emphasized the impact of this breakthrough:
“The intricacies of human biology make the development of any AI technology incredibly complex. However, with the support of our new investors, we are excited to fulfill the potential of Ingenix and change the way clinical trials are conducted.”
Backing from Leading Deep Tech Investors
The round was led by Inovo Fund 3, which aims to deploy over €100 million in the CEE startup ecosystem. Inovo has previously backed other healthtech and AI companies like Infermedica and Jutro Medical.
OTB Ventures, a leading deep tech investor supported by the NATO Innovation Fund and the European Investment Fund, also joined the round via OTB Fund 2. The fund recently closed at $185 million and focuses on breakthrough solutions in health, cybersecurity, and AI.
The International Finance Corporation (IFC)—part of the World Bank Group—rounded out the group of investors. Their involvement supports the development of scalable, AI-based clinical tools that can benefit not only developed healthcare systems but also emerging markets.
Accelerating Access to Safer and Faster Therapies
The funding will allow Ingenix to scale its simulations and make them accessible across pharmaceutical pipelines. By drastically improving prediction models for efficacy and adverse events, the company aims to cut down the average 10-15 year development cycle and reduce the enormous financial risks faced by drug developers.
This move signals a larger shift in the healthcare industry, where generative AI is beginning to play a crucial role in biomedical research, regulatory testing, and global health equity.
Ingenix is now positioned to become one of the most significant digital health companies in Europe, with its AI platform offering a faster, safer, and more cost-effective path to medical innovation.
